A Phase I study of Anetumab Ravtansine in Combination with either Anti-PD-1 Antibody or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma

Brief description of study

The purpose of the study is to determine the side effects and best dose of anetumab ravtansine when given together with nivolumab, ipilimumab and gemcitabine hydrochloride in treating patients with mesothelin positive pancreatic cancer that has spread to other places in the body. Anetumab ravtansine is a new drug that targets a protein called mesothelin. The purpose of this study is to test the safety of the drug combinations anetumab ravtansine and nivolumab (Group 1) or nivolumab and ipilimumab (Group 2) or gemcitabine and nivolumab (Group 3). The study drug combination of anetumab ravtansine together with nivolumab, ipilimumab, and gemcitabine hydrochloride is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s20-01390
ClinicalTrials.gov Identifier: NCT03816358
Principal Investigator: Paul E. Oberstein.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.